664 results about "Bacteriuria" patented technology

A method for treating congestive heart failure (CHF) has been developed that restores kidney renal functions by artificial vasodilation of at least one kidney. A vasodilator drug is locally delivered to the kidney via a kidney perfusion catheter. The drug can be mixed with the patient's blood, saline or other suitable solvent and the mixture directly applied to the kidney through the catheter. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances. The method is applicable to treat chronic and acute CHF.

Methods, devices and test kits for monitoring the ovulation cycle, involve testing the body fluid, e.g. urinary, concentration of one or more analytes. Preferably estrone-3-glucuronide and luteinizing hormone are both measured, and a reference concentration for E3G is established at about day 6 of the current cycle. Preferably, disposable testing devices are used, in conjunction with a relatively permanent electronic reader/monitor. The number of "daily" tests required per month can be minimized.

MK (midkine) was found to rise in the blood or urine of patients with various types of cancers at early stage. Based on this finding, a method for detecting early cancer, comprising the step of measuring MK in blood or urine was completed.

The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer.

ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip. Gene expression in bladder cancer was validated using reverse transcription-polymerase chain reaction (RT-PCR), quantitative PCR, and in situ hybridization. Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.

The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.

Particularly ADAM12 mRNA expression was significantly upregulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage. ADAM12 protein expression correlated with tumor stage and grade. ADAM12 was present in higher levels in the urine from bladder cancer patients than in urine from healthy individuals. Significantly, following removal of tumor by surgery, in most bladder cancer cases examined the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.

The present invention relates to peptides of one or more portions of the human chorionic gonadotropin beta-chain as well as methods of promoting hematopoiesis, using human chorionic gonadotropin, employing the beta-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the beta-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or perparations of human chorionic gonadotropin, such as fractions of humna early pregnancy urine, which fractions have pro-hematopoietic activity. The present invention further relates to pharmaceutical compositions for promoting hematopoiesis.

Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.

ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient.

An apparatus comprising a sensing unit configured to predict a release of urine using one or more prediction parameters, detect an actual release of urine and adapt at least one of the one or more prediction parameters based on the actual release of urine to increase prediction accuracy.

The invention relates to a pathological examination, in particular to a liquid-based cell preservation solution used in cytopathological examination of human cervical mucus, sputum, urine, pleural fluid, tracheal mucus and the like. It is characterized in that it is prepared from alcohols, sodium phosphate buffer, edetate disodium, sodium chloride 0.08%-0.12%, potassium chloride, formaldehyde, dithiothreitol, calcium acetate, magnesium acetate, etc. As a result, it can not only maintain the stability of the cell structure. It can reduce the agglomeration and precipitation of cell mucus and the loss of cell rupture, and can also make cells easy to stain, improve the clarity of cell preparation, facilitate the smooth progress of pathological examination, and the cost is low, which is conducive to popularization and use.

A bear derived isolate found in denning black bears or black bears from which food has been withheld for at least two weeks when injected into another mammal produces reduced heart rate, reduced respiratory rate, reduced temperature, and a wakeful tranquility not unlike the phenomena of the denning black bear. The isolate is taken from either the serum or urine of such denning bear. The method of the invention involves the steps of fractionating the serum or urine of a denning black bear to produce fractions of varying potency.

A system and method evaluates a patient for stress urinary incontinence. An involuntary reflex cough event is induced within the patient that activates the nucleus ambiguous and medial motor cell column of the patient and stimulates involuntary cough activated paraspinal muscles in the pelvis of the patient. And elecromyogram (EMG) is obtained from the involuntary cough activated paraspinal muscles and its duration determined. Any urine leakage time that occurs during the involuntary reflex cough event is identified and correlated within a processor together with the urine leakage time and EMG and duration of cough event to determine stress urinary incontinence.

The invention provides methods of detecting cancerous cells in biological samples using a double staining/dual imaging approach, which can be used to diagnose cancer. More specifically, the present invention provides methods of diagnosing bladder cancer by a simultaneous scanning of cell morphology and FISH signals of cells derived from a urine sample.

The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the β-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the β-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the β-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.

The invention provides a method for detecting alternative biological markers of liver neoplasms in saliva, serum and urine so as to detect expression information of alternative biological markers of liver neoplasms in a rapid, convenient and accurate manner. The method mainly comprises the following steps of: 1) preparing agglutinin chips corresponding to detection of saliva, serum and urine samples respectively; 2) pretreating stock solutions of saliva, serum and urine samples, removing impurities and purifying proteins, labeling by using a fluorescent reagent and removing redundant fluorescence by using G-25 columns to obtain corresponding samples to be detected; and 3) respectively loading three samples to be detected onto corresponding agglutinin chips to obtain respective glycoprotein sugar chain spectrum in each sample to be detected, and obtain information of the alternative biological markers according to reaction results of any sample to be detected. By the method, the sensibility during detection is high and detection results are accurate; moreover, the method has the advantages of safety, no damage, convenience for sample collection, simplicity in storage and the like.

A urinary directional device for improving the directional urination and health of a male user is provided, in which the device comprises a conduit for the passage of urine and having a proximal end adapted for engagement with the penis of the user and a distal end having a distal aperture to enable the passage of urine from the conduit, the device having an interior surface providing one or more of a cleansing, an anti-bacterial or antiseptic or an anti-fungal function whereby the penis of the user can be cleansed by wiping on the interior surface of the device after urination and the device optionally further comprising a health detection indicator capable of indicating abnormalities in urine indicative of disease or health-related conditions.

The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut. An H2S or lactulose breath test and/or detection of H2S or thiosulfate in the blood or urine may be used as a diagnostic and/or prognostic for assessing a systemic H2S load that exceeds a mammal's natural detoxification capacity. These tests may similarly be used to monitor the effectiveness of a therapeutic intervention for SIBO and/or the diseases or physiologic conditions whose pathology is linked thereto. Because SIBO is related to hyperhomocysteinemia, diseases and physiologic conditions that relate to hyperhomocysteinemia may further be monitored and treated in connection with the methods of the present invention.

Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascular diseases.

The invention discloses a determination method of a urine metabolic marker for early diagnosis of diabetic nephropathy. The method mainly utilizes analysis technique and method such as gas mass spectrometry and mass liquid spectrometry for quantitative determination of endogenous small molecule compounds in urine of patients with diabetes and diabetic nephropathy; and relative concentration difference between endogenous small molecule compounds in a pathological group and a normal group is calculated and compared, so as to be applied to clinical early diagnosis of diabetic nephropathy. Compared with other existing clinical diagnosis indexes, the method has advantages of wide adaptation range, sensitivity, simple sampling and operation, and no harm on the body. The method is more suitable for screening of diabetic nephropathy in early stage with some uncertain physiological and biochemical indexes, so as to avoid missing of the best treatment time due to delayed diagnosis.

Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and/or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed.

An extra-labia urine voiding apparatus including a container sized and shaped to externally cover a vulval region of a female anatomy. The container has an open side and defines a reservoir that is adapted for receiving urine. The container also includes a substantially planar surface disposed at a top of the container adapted to face and generally surround a periphery of the vulval region. An extra-labia sealing structure is affixed to the planar surface of the top of the container. The sealing structure includes a pressure sensitive adhesive adapted to provide a generally fluid tight primary adhesive seal between the container and external tissue generally surrounding the vulval region. A blocking mechanism connected proximate the top of the container prevents escape of urine from the voiding apparatus and contact of urine with the vulval region of the female anatomy. The voiding apparatus also includes a conduit in fluid communication with the reservoir of the container and adapted for draining urine from the reservoir.

A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and/or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.

The invention provides a bladder cancer patient urine specific metabolite spectrum, an establishing method and an application, and especially provides a method for establishing a spectrum of specific metabolites in urine of bladder cancer patients, and a method for screening a related specific biomarker. Through metabonomics, especially metabonomics based on liquid chromatography-mass spectrometry combined technology, the invention establishes a bladder cancer patient urine specific metabolite spectrum. The invention provides a basis for early diagnosis of bladder cancer and bladder cancer diseases with different pathological stages, and also provides a spectrum of specific metabolites in urine of bladder cancer patients and a related specific biomarker. The method provided by the invention has the characteristics of noninvasiveness, convenience, and rapidness, can accurately reflect the difference of metabolite spectra of bladder cancer patients and normal people, and has high specificity.